Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 2
2006 4
2007 1
2008 3
2009 3
2010 6
2011 7
2012 3
2013 11
2014 19
2015 18
2016 28
2017 39
2018 30
2019 29
2020 28
2021 36
2022 40
2023 45
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Results by year

Filters applied: . Clear all
Page 1
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends CM, Kopp K, Hablesreiter R, Estrada N, Christen F, Moll UM, Zeillinger R, Schmitt WD, Sehouli J, Kulbe H, Fleischmann M, Ray-Coquard I, Zeimet A, Raspagliesi F, Zamagni C, Vergote I, Lorusso D, Concin N, Bullinger L, Braicu EI, Damm F. Arends CM, et al. Among authors: lorusso d. Leukemia. 2024 Apr 18. doi: 10.1038/s41375-024-02253-3. Online ahead of print. Leukemia. 2024. PMID: 38637689
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Sukhin V, Cloven N, Pereira de Santana Gomes AJ, Contreras Mejía F, Reiss A, Ayhan A, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Lazzari R, Chang CL, Lampé R, Zhu H, Oaknin A, Christiaens M, Polterauer S, Usami T, Li K, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR; ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators. Lorusso D, et al. Lancet. 2024 Apr 6;403(10434):1341-1350. doi: 10.1016/S0140-6736(24)00317-9. Epub 2024 Mar 20. Lancet. 2024. PMID: 38521086 Clinical Trial.
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Passarelli A, Carbone V, Pignata S, Mazzeo R, Lorusso D, Scambia G, Canova S, Di Palma T, Tasca G, Mantiero M, Naglieri E, Andreetta C, Rauso M, Brunetti AE, Laera L, Abeni C, Scandurra G, Gambaro AR, Pastore A, Bengala C, Gunnellini M, Farolfi A, Spinello M, Bartoletti M. Passarelli A, et al. Among authors: lorusso d. Gynecol Oncol. 2024 Mar 21;183:61-67. doi: 10.1016/j.ygyno.2024.02.029. Online ahead of print. Gynecol Oncol. 2024. PMID: 38518529 Free article.
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Among authors: lorusso d. Future Oncol. 2024 Mar 19. doi: 10.2217/fon-2023-0782. Online ahead of print. Future Oncol. 2024. PMID: 38501262 Free article. Review.
Reply to P.-H. Luo et al.
Monk BJ, Colombo N, Tewari KS, Tekin C, Keefe SM, Lorusso D. Monk BJ, et al. Among authors: lorusso d. J Clin Oncol. 2024 May 1;42(13):1596-1598. doi: 10.1200/JCO.24.00077. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452314 No abstract available.
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
Bartoletti M, Montico M, Lorusso D, Mazzeo R, Oaknin A, Musacchio L, Scambia G, Puglisi F, Pignata S. Bartoletti M, et al. Among authors: lorusso d. Cancer Treat Rev. 2024 Apr;125:102701. doi: 10.1016/j.ctrv.2024.102701. Epub 2024 Feb 27. Cancer Treat Rev. 2024. PMID: 38422895 Free article. Review.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Arezzo F, Giannone G, Castaldo D, Scotto G, Tuninetti V, Turinetto M, Bartoletti M, Mammoliti S, Artioli G, Mangili G, Salutari V, Lorusso D, Cormio G, Loizzi V, Zamagni C, Savarese A, Di Maio M, Ronzino G, Pisano C, Pignata S, Valabrega G. Arezzo F, et al. Among authors: lorusso d. Front Oncol. 2024 Jan 22;13:1357793. doi: 10.3389/fonc.2023.1357793. eCollection 2023. Front Oncol. 2024. PMID: 38318323 Free PMC article.
330 results